EU MDR – Person Responsible for Regulatory Compliance (PRRC)
The EU Medical Devices Regulation (MDR) lays down the rules regarding the placing on the market, making available on the market or putting into service of medical devices and accessories for such devices. When compared to the prior applicable Directives, the MDR (and also IVDR) makes it mandatory for manufacturers to have within their organizations at least one Person Responsible for Regulatory Compliance.
Liliana Teles

Liliana Teles

Regulatory Affairs Manager

MDR, IVDR AND PRRC

In 2017, two Regulations on medical devices and in in vitro diagnostic medical devices entered into force in the European Union (EU), progressively replacing the 3 existing Directives. The main goal was to establish a modernized and more robust EU legislative framework and to safeguard a better public health protection and patient safety.

The EU Medical Devices Regulation (MDR – Regulation (EU) 2017/745) lays down the rules regarding the placing on the market, making available on the market or putting into service of medical devices for human use (and accessories for such devices). The Regulation (EU) 2017/746 sets out the rules on in vitro diagnostic medical devices (IVDR).

According to Article 15 of both Regulations, it is mandatory for manufacturers to have, within their organization (as an employee), a person responsible for regulatory compliance (PRRC). Importers and Authorized Representatives must also have an PRRC. The PRRC must possess requisite expertise in the field of medical devices, which shall be demonstrated with one of the following qualifications:

  • Four years of professional experience in regulatory affairs or in quality management systems relating to medical devices;
  • Diploma, certificate (or other formal qualification) from a university degree in law, medicine, pharmacy, engineering or other relevant scientific discipline (recognized as equivalent by the Member State concerned) and at least one year of professional experience in regulatory affairs or in quality management systems relating to medical devices.

If the qualification was obtained outside the EU it must be recognized by an EU Member State as equivalent to the EU corresponding qualification. The professional experience should be related to the EU requirements in the field.

The PRRC is responsible for the technical documentation, EU Declaration of Conformity (drawn up and kept up-to-date), post-market surveillance obligations and checking the conformity of devices before they are released (according to the quality management system implemented). Vigilance activities, recording and reporting incidents, safety and performance requirements, clinical investigations and performance studies are also among the responsibilities and roles of the PRRC.

Each legal manufacturer must have its own PRRC. The PRRC must be close to the manufacturer, which means that if the manufacturer is located in the EU, its PRRC must also be located in the EU.

When it comes to micro and small manufacturers, they may subcontract the responsibilities of a PRRC to a third party, but it must be available permanently and continuously to them. This is also the case for Authorized Representatives, who may also outsource this role. The PRRC of an Authorized Representative (AR) is responsible for ensuring that the tasks of the AR (as specified in the given mandate) are fulfilled.

An AR and a manufacturer established outside the EU cannot have the same PRRC, ensuring a higher level of scrutiny and that the supervision and control of the production of devices, post-market surveillance and vigilance activities are effectively performed. For the same purpose, the PRRC of a micro and small manufacturer and the PRRC of the AR of that same company shall not belong to the same external organization.

References:

  1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices.
  2. Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices.
  3. MDCG 2019-7 – Guidance on Article 15 of the Medical Device Regulation (MDR) and in vitro Diagnostic Device Regulation (IVDR) regarding a “person responsible for regulatory compliance” (PRRC).

further
reading

cosmetic products

New Formaldehyde Threshold in Cosmetic Products

The European Commission has issued a draft regulation to amend the preamble of Annex V regarding the threshold for labelling formaldehyde releasers. This amendment results from a scientific advice published by the SCCS concluding that the current threshold does not sufficiently protect consumers sensitized to formaldehyde.

Read More »
cosmetic products

New Restriction on the Use of Benzophenone-3 in Cosmetics

Benzophenone-3 was part of a priority list of potential endocrine disruptors established by the European Commission in 2019. The SCCS was asked to assess the safety of this ingredient and the European Cosmetics Regulation will be amended in accordance with the SCCS assessment conclusions.

Read More »
endocrine disruptors
cosmetic products

European Commission Calls for Data on Ingredients with Potential Endocrine-Disrupting Properties

Substances classified as endocrine disruptors are compounds that can alter the functioning of the endocrine system and negatively affect the health of humans and animals. In 2019, the European Commission set out two lists of ingredients suspected of having endocrine disrupting properties. More recently, the Commission has published a call for data for 10 ingredients that were included in the low priority group (Group B) for the SCCS to be able to assess their safety.

Read More »
cosmetic products

SCCS Preliminary Opinion on Prostaglandins and Prostaglandin-analogues

Following the mandate from the European Commission, the Scientific Committee on Consumer Safety (SCCS) has published a preliminary opinion on Prostaglandins and Prostaglandin-analogues used in cosmetic products. This preliminary opinion is open for comments and the deadline was set for 23 november 2021.

Read More »
cosmetic products

SCCS Preliminary Opinion on Butylated Hydroxytoluene (BHT)

Following the mandate from the European Commission, the Scientific Committee on Consumer Safety (SCCS) has published a preliminary opinion on Butylated Hydroxytoluene (BHT). This preliminary opinion is open for comments and the deadline was set for 23 november 2021.

Read More »
cosmetic products

EU Prohibition of Zinc Pyrithione in Cosmetic Products

Zinc Pyrithione has been used for more than 60 years as an anti-dandruff agent in cosmetic products. Last month, the European Commission published the Commission Regulation (EU) 2021/1092, which includes this ingredient in Annex II. From March 2022 onwards, Zinc Pyrithione will be prohibited in cosmetic products.

Read More »
medical devices

EUDAMED Status Update 2021

The development and deployment of EUDAMED is progressing. Following the implementation plan and getting familiar with the information stored in the database’s modules is crucial for economic operators compliance in the EU market.

Read More »
cosmetic products

EU Chemicals Strategy for Sustainability

The Chemicals Strategy for Sustainability (CSS) was recently published by the European Union. The CSS is part of the European Green Deal which aims for a toxic-free environment leading to zero pollution. The initiative proposes a new legislative amend to the EU Cosmetic Products Regulation. Simplification and digitalization of labelling requirements plus review of the definition of nanomaterial are two of the main objectives of the CSS.

Read More »
cosmetic products

Nanotechnology in Sun Care Products

Nanomaterials are increasingly used in cosmetics and personal care products. They are similar to other chemicals/substances, but with specific risks associated to their use. Currently, there are 4 nano-ingredients approved in the European Union for use as UV filters in cosmetic products.

Read More »
cosmetic products

May Butylphenyl Methylpropional be used in Cosmetic Products?

Butylphenyl Methylpropional, also known as Lilial, is a fragrance ingredient that has been used for years in several cosmetic and non-cosmetic products. Nevertheless, some concerns have been expressed regarding the use of this ingredient and its risk to consumers. According to an amendment to the CLP Regulation, the use of Butylphenyl Methylpropional will be prohibited in cosmetic products from 1st March 2022.

Read More »
cosmetic products

How are Cosmetic Products Regulated in the United Arab Emirates?

The United Arab Emirates (UAE) are an emerging market for the beauty industry. Cosmetics and personal care products supplied or sold in the UAE must comply with the health and safety requirements set out in UAE legislation. Overall, the process for importing a cosmetic product into the UAE market from the European Union can be quite straightforward since the UAE has aligned several of its requirements with the European Cosmetic Regulation.

Read More »